Orthodontic Practice Valuation, 2026 Updated Report
Orthodontic practices remain one of the most stable assets in healthcare M&A. The specialty benefits from predictable cash flow, a largely private-pay base, and expanding consolidation by dental service organizations (DSOs) seeking recurring patient relationships. Even amid higher borrowing costs and regulatory volatility, buyer competition and disciplined platform formation have sustained elevated valuations.
Key takeaways:
Platform orthodontic groups commonly trade between 9–11× EBITDA and 1.4–1.8× revenue, consistent with 2026 DSO benchmarks.
Add-on practices typically achieve 5–8× EBITDA, reflecting integration potential and limited infrastructure.
Private-pay revenue mix >70% continues to attract private equity and family-office investors seeking margin protection.
69% of DSOs report that their PE sponsors expect a moderate or high increase in 2026 acquisition activity, while 78% anticipate a recapitalization within 12 to 36 months. (TUSK Practice Sales, Q2 2026)
Orthodontic platforms now represent roughly one-third of all dental M&A, signaling durable consolidation momentum into 2026.
Market Overview 2026
According to reports, overall healthcare-services deal volume rose 6% quarter-over-quarter, with physician and dental group transactions driving 24% of all M&A. Dental and orthodontic practices led that category: nine of the most active acquirers were DSOs, and all but one were PE-backed. Data shows private equity accounted for 41% of all U.S. healthcare deals, with physician and dental assets commanding a disproportionate share of disclosed valuations.
Since 2021, dental practices have accounted for approximately 37% of all transactions in the Physician Medical Group sector, a volume exceeding that of Behavioral Health Care, Home Health & Hospice, and Medical Outpatient Buildings combined. The DSO market itself is projected to grow by nearly 17% by 2030, underpinned by the fact that only 16% of the estimated 200,000 U.S. dentists are currently affiliated with a DSO, leaving significant runway for consolidation. (LevinPro HC, 2026 Healthcare M&A Outlook)
Bain’s 2025 Global Healthcare Private Equity Report reinforces the trend: mid-market sponsors continue to outperform larger funds through specialization. In healthcare, a significant portion of PE activity has involved provider-service roll-ups. Dental, eye care, and behavioral health remain the most consistently traded subsectors, delivering predictable exits despite macro uncertainty.
In this context, orthodontic practices strike an ideal balance between scalability and defensible economics. Recurring treatment revenue, minimal reimbursement risk, and strong ancillary economics (imaging, aligners, in-house labs) support above-median multiples even as broader healthcare EBITDA averages have plateaued around 11.5×.
| Deal Type | EV/EBITDA Multiple (Typical) | Revenue Multiple (Typical) | Key Drivers |
|---|---|---|---|
| Platform (≥ 5 locations or $3M EBITDA plus) | 9 – 11× | 1.4 – 1.8× | Scale, regional density, management infrastructure |
| Add-on (1 – 4 locations or $1-3M EBITDA) | 5 – 8× | 1.0 – 1.3× | Integration synergies, local referral base |
| Solo practice | 4 – 6× | ~ 1.0× | Owner dependence, limited systems |
| Ortho + Pedo hybrid | 9 – 12× | 1.5 – 1.9× | Cross-referrals, broader demographics served |
Based on works cited and directional banker guidance. Actual pricing varies with each transaction based on many factors. Intended for educational purposes only and not a guarantee of any outcome.
Valuation Drivers and Premium Factors
Even within standard ranges, valuation dispersion has widened as investors reward technology adoption and operational maturity.
Technology enablement: Widespread adoption of digital scanners, 3D imaging, and AI-assisted treatment planning has shortened case-start cycles and improved throughput. Practices with integrated aligner production or in-house labs can see EBITDA lift relative to peers. Notably, AI-powered operational tools are now allowing some DSOs to reduce non-clinical labor costs by an estimated 20–50%, a dynamic that increasingly factors into buyer underwriting.
Recurring revenue mix: Subscription-based aligner programs and long-term treatment plans have become favored models for EBITDA stability. Buyers value predictable cash flow more than case volume growth.
Infrastructure and back-office systems: Centralized revenue cycle management and patient-communication platforms reduce integration risk. VMG Health notes that leading platforms increasingly treat EMR standardization and data integrity as enterprise-level assets, directly supporting stronger diligence outcomes and investor confidence. (VMG Health, January 2026)
Private-pay dominance: Practices with >75% private-pay revenue or transparent financing arrangements consistently achieve premium outcomes versus insurance-heavy models.
Succession and leadership: Retained clinical leadership is essential for sponsor interest across the provider services investing landscape. Buyers are now more consistently requiring a minimum 5-year post-close employment term. Longer transition plans, a deeper provider bench, and aligned partnership structures are highly attractive to investors. Over-reliance on a single clinical producer has become a leading reason investors walk from deals.
Private Equity Landscape and Platform Formation
Levin Associates reports that in Q3 2025 alone, DSOs accounted for 67 transactions in the “physician-group” category, representing roughly one-third of total healthcare services deals. Dental365, Specialized Dental Partners, Imagen Dental Partners, and SALT Dental Partners each completed three to four acquisitions during the quarter, demonstrating continued momentum at a time when many other healthcare verticals were slowing.
PitchBook’s Q2 update similarly found that “all the -ologies have stabilized,” with dentistry and orthodontics among the few specialties still commanding premium valuations as top-tier assets. Bain’s analysis of exit strategies shows that platforms with EBITDA between $10 to $25 million remain the most tradable due to manageable debt loads and strong add-on pipelines.
Although interest rates remain high, data show that private firms still comprise 72% of all acquirers in healthcare and announced 222 deals with financial sponsors, up 13% from the prior quarter.
Several marquee transactions in 2025 illustrate the depth of institutional conviction in the dental category. GTCR’s $1.58 billion acquisition of Dentalcorp and Ontario Teachers’ $1.2 billion investment in Donte Group anchor valuation expectations for the sector. Warburg Pincus added to that signal with a $525 million strategic investment in MB2 Dental, which, alongside Heartland Dental, ranked as one of the two most active dental acquirers in both 2024 and 2025. These transactions effectively set the valuation floor for orthodontic platform expectations heading into 2026 and 2027. (LevinPro HC, 2026 Healthcare M&A Outlook)
Many active DSO buyers anticipate a recapitalization within 12 to 36 months, meaning dentists and orthodontists who sell in 2026 are negotiating with platforms that are actively preparing for exit.
A note on seller supply: An emerging structural dynamic deserves attention. According to the American Dental Association, some states now have more than 40% of their active dentists aged 55 or older, and the average retirement age for U.S. dentists reached 68.7 years in 2024. When this retirement cohort brings practices to market in volume, the competitive dynamics that currently favor sellers are likely to shift. Practice owners within 3 to 7 years of a transition should evaluate their position now. (ADA Health Policy Institute, 2025 Update)
Margins and Financial Profile
Orthodontic practices exhibit healthy margin consistency relative to other outpatient specialties. VMG Health’s 2025 report places average EBITDA margins between 22% and 26% and same-store growth around 4–6% annually, driven by aligner volume and marketing automation.
| Metric | Typical Range | Commentary |
|---|---|---|
| EBITDA Margin | 22–26% | Stable due to fixed staff leverage and recurring patient plans |
| Same-Store Growth | 3–7% | Marketing automation and referral programs |
| De Novo Ramp Time | 12–18 mo | Longer in dense metros; faster in underserved regions |
| Private-Pay Mix | 70–85% | Core valuation driver across all models |
| Average Deal Size | $15–35 M | Typical for regional multi-site practices |
Labor cost inflation and interest rates remain pressures, but price elasticity in orthodontic services is high relative to medical segments. Scope Research data show that size-to-multiple relationships flatten above $10 million in EBITDA, indicating that buyers value efficiency and growth narrative as much as scale.
Regulatory and Macroeconomic Context
Policy changes through the 2025 One Big Beautiful Bill Act have created uncertainty for Medicaid-exposed segments, but orthodontics has minimal dependence on government reimbursement. This insulation supports valuation stability while other provider verticals face margin compression. Furthermore, research notes that the U.S. Federal Reserve’s rate hold in mid-2025 helped restore deal confidence by signaling a plateau in borrowing costs.
On the upside, a new insurance reform wave may benefit providers. Throughout 2025, multiple states moved to enact dental loss ratio (DLR) requirements, which mandate that dental insurers spend a minimum percentage of premiums on patient care or refund the difference. Montana, North Dakota, and Washington have already passed DLR laws, and momentum is building for broader adoption in 2026. For orthodontic practices with any commercial insurance exposure, higher reimbursements from these reforms could provide a modest earnings tailwind. (LevinPro HC, 2026 Healthcare M&A Outlook)
The U.S. Federal Reserve held rates steady in March 2026, continuing a plateau in borrowing costs and helping sustain deal confidence. State-level oversight of PE-owned healthcare assets has intensified (Oregon’s SB 95 and similar bills in Washington and Massachusetts), but dental transactions remain largely outside the hospital and payer scrutiny zone, another factor sustaining investor interest.
2026–2027 Outlook
Forecasts show steady transaction momentum through mid-2026 as platforms pursue geographic expansion and ancillary integration. Exit-value analysis suggests multiples will likely plateau near current levels before rising slightly if further rate cuts take effect. For orthodontics, the key themes are expected to include:
Digital workflow optimization: Expansion of AI-driven case planning and chair-time efficiency software. AI tools are already helping DSOs reduce non-clinical labor costs significantly, and practices that have adopted these systems are likely to command attention from tech-forward acquirers.
Vertical integration: Investment in imaging centers and in-office manufacturing to capture margin upstream.
Hybrid ownership models: Continued use of clinician rollover equity to align interests and retain leadership.
Regional fragmentation opportunities: Midwestern and Southeastern U.S. remain under-consolidated, offering attractive entry valuations.
De Novo evolution: As AI matures, some PE-backed platforms may increasingly favor building new locations over acquiring existing ones, particularly in markets where startup economics become more favorable than integration costs. This shift, while still emerging, will reward existing sellers who act before the acquisition-vs-build calculus meaningfully changes.
While EBITDA multiples for large platforms may not expand materially, smaller regional operators could see compression as capital shifts toward strategic buy-and-build plays. Still, orthodontics is poised to remain one of the top three most active healthcare services subsectors through 2027.
Learn More
FOCUS Investment Banking specializes in maximizing transaction value for healthcare practice owners through our proven quarterback approach to M&A advisory.
If you’d like to learn more about our healthcare investment banking services, you can reach out here.
Sources
Dental Service Organizations M&A in 2026 (January 29, 2026)
